Overall survival outcomes in MATTERHORN trial support perioperative durvalumab plus chemotherapy as standard of care.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback